These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35334416)

  • 1. Prognostic impact of inflammation in malignant pleural mesothelioma: A large-scale analysis of consecutive patients.
    Fournel L; Charrier T; Huriet M; Iaffaldano A; Lupo A; Damotte D; Arrondeau J; Alifano M
    Lung Cancer; 2022 Apr; 166():221-227. PubMed ID: 35334416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between prognosis and neutrophil: lymphocyte and platelet:lymphocyte ratios in patients with malignant pleural mesotheliomas.
    Cihan YB; Ozturk A; Mutlu H
    Asian Pac J Cancer Prev; 2014; 15(5):2061-7. PubMed ID: 24716935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammation-based prognostic indices in malignant pleural mesothelioma.
    Pinato DJ; Mauri FA; Ramakrishnan R; Wahab L; Lloyd T; Sharma R
    J Thorac Oncol; 2012 Mar; 7(3):587-94. PubMed ID: 22307011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.
    Banna GL; Addeo A; Zygoura P; Tsourti Z; Popat S; Curioni-Fontecedro A; Nadal E; Shah R; Pope A; Fisher P; Spicer J; Roy A; Gilligan D; Gautschi O; Janthur WD; López-Castro R; Roschitzki-Voser H; Dafni U; Peters S; Stahel RA
    Lung Cancer; 2022 Jul; 169():77-83. PubMed ID: 35660972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board.
    Kao SC; Vardy J; Chatfield M; Corte P; Pavlakis N; Clarke C; van Zandwijk N; Clarke S
    Clin Lung Cancer; 2013 Jan; 14(1):70-7. PubMed ID: 22658812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.
    Ghanim B; Klikovits T; Hoda MA; Lang G; Szirtes I; Setinek U; Rozsas A; Renyi-Vamos F; Laszlo V; Grusch M; Filipits M; Scheed A; Jakopovic M; Samarzija M; Brcic L; Stancic-Rokotov D; Kern I; Rozman A; Dekan G; Klepetko W; Berger W; Glasz T; Dome B; Hegedus B
    Br J Cancer; 2015 Mar; 112(5):783-92. PubMed ID: 25633038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales.
    Linton A; Pavlakis N; O'Connell R; Soeberg M; Kao S; Clarke S; Vardy J; van Zandwijk N
    Br J Cancer; 2014 Oct; 111(9):1860-9. PubMed ID: 25188323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma.
    Yamagishi T; Fujimoto N; Nishi H; Miyamoto Y; Hara N; Asano M; Fuchimoto Y; Wada S; Kitamura K; Ozaki S; Kishimoto T
    Lung Cancer; 2015 Oct; 90(1):111-7. PubMed ID: 26259877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival by Histologic Subtype of Malignant Pleural Mesothelioma and the Impact of Surgical Resection on Overall Survival.
    Verma V; Ahern CA; Berlind CG; Lindsay WD; Shabason J; Sharma S; Culligan MJ; Grover S; Friedberg JS; Simone CB
    Clin Lung Cancer; 2018 Nov; 19(6):e901-e912. PubMed ID: 30224273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy.
    Kao SC; Klebe S; Henderson DW; Reid G; Chatfield M; Armstrong NJ; Yan TD; Vardy J; Clarke S; van Zandwijk N; McCaughan B
    J Thorac Oncol; 2011 Nov; 6(11):1923-9. PubMed ID: 22011651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma.
    Lim JH; Choi JY; Im Y; Yoo H; Jhun BW; Jeong BH; Park HY; Lee K; Kim H; Kwon OJ; Han J; Ahn MJ; Kim J; Um SW
    PLoS One; 2020; 15(2):e0229299. PubMed ID: 32069313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Investigation of Cancer-Directed Surgery for Different Histologic Subtypes of Malignant Pleural Mesothelioma.
    Mansur A; Potter AL; Zurovec AJ; Nathamuni KV; Meyerhoff RR; Berry MF; Kang A; Jeffrey Yang CF
    Chest; 2023 May; 163(5):1292-1303. PubMed ID: 36574925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data.
    Pasello G; Urso L; Mencoboni M; Grosso F; Ceresoli GL; Lunardi F; Vuljan SE; Bertorelle R; Sacchetto V; Ciminale V; Rea F; Favaretto A; Conte P; Calabrese F
    Oncotarget; 2015 Dec; 6(39):42053-66. PubMed ID: 26544728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
    Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
    Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computed tomography in the evaluation of malignant pleural mesothelioma-Association of tumor size to a sarcomatoid histology, a more advanced TNM stage and poor survival.
    Paajanen J; Laaksonen S; Ilonen I; Wolff H; Husgafvel-Pursiainen K; Kuosma E; Ollila H; Myllärniemi M; Vehmas T
    Lung Cancer; 2018 Feb; 116():73-79. PubMed ID: 29413055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database.
    Meyerhoff RR; Yang CF; Speicher PJ; Gulack BC; Hartwig MG; D'Amico TA; Harpole DH; Berry MF
    J Surg Res; 2015 Jun; 196(1):23-32. PubMed ID: 25791825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
    Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
    Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma.
    Kircheva DY; Husain AN; Watson S; Kindler HL; Durkin A; Vigneswaran WT
    Eur J Cardiothorac Surg; 2016 Jun; 49(6):1642-7. PubMed ID: 26802143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma.
    Kadota K; Villena-Vargas J; Nitadori J; Sima CS; Jones DR; Travis WD; Adusumilli PS
    Ann Surg Oncol; 2015 Sep; 22(9):3136-43. PubMed ID: 25608772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic values of preoperative C-reactive protein, albumin, and neutrophil ratios in patients with malignant pleural mesothelioma who underwent extrapleural pneumonectomy.
    Okita R; Okada M; Inokawa H; Murakami T; Ikeda E
    Surg Oncol; 2022 Aug; 43():101813. PubMed ID: 35816852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.